MannKind Corporation (MNKD): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

MannKind Corporation ( MNKD) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.8%. By the end of trading, MannKind Corporation fell $0.19 (-2.5%) to $7.46 on average volume. Throughout the day, 6,615,482 shares of MannKind Corporation exchanged hands as compared to its average daily volume of 7,029,300 shares. The stock ranged in price between $7.30-$7.66 after having opened the day at $7.46 as compared to the previous trading day's close of $7.65. Other companies within the Drugs industry that declined today were: China Biologic Products ( CBPO), down 12.9%, Prima Biomed ( PBMD), down 10.2%, Skystar Bio-Pharmaceutical Company ( SKBI), down 10.1% and Oxygen Biotherapeutics ( OXBT), down 9.9%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States. MannKind Corporation has a market cap of $2.2 billion and is part of the health care sector. Shares are up 221.6% year to date as of the close of trading on Thursday. Currently there are 4 analysts that rate MannKind Corporation a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates MannKind Corporation as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, poor profit margins and weak operating cash flow.

On the positive front, Prothena Corporation ( PRTA), down 13.8%, Vanda Pharmaceuticals ( VNDA), down 9.5%, Ariad Pharmaceuticals ( ARIA), down 9.2% and NewLink Genetics ( NLNK), down 9.0% , were all gainers within the drugs industry with Gilead ( GILD) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Mannkind in Free Fall After Changes to Insulin Product, Sales Force

Mannkind Stock Drops Following Changes to Its Insulin Product

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Insulin Drug Offers Hope for MannKind